Format

Send to

Choose Destination
Endocr Relat Cancer. 2016 Mar;23(3):147-59. doi: 10.1530/ERC-15-0383. Epub 2015 Dec 8.

TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.

Author information

1
Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
2
Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
3
Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada Translational Ovarian Cancer Research ProgramLondon Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6Department of Anatomy and Cell BiologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of BiochemistrySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of Obstetrics and GynaecologySchulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, CanadaDepartment of OncologySchulich School of Medicine and Dentistry, The University o

Abstract

Epithelial-mesenchymal transition (EMT) serves as a key mechanism driving tumor cell migration, invasion, and metastasis in many carcinomas. Transforming growth factor-beta (TGFβ) signaling is implicated in several steps during cancer pathogenesis and acts as a classical inducer of EMT. Since epithelial ovarian cancer (EOC) cells have the potential to switch between epithelial and mesenchymal states during metastasis, we predicted that modulation of TGFβ signaling would significantly impact EMT and the malignant potential of EOC spheroid cells. Ovarian cancer patient ascites-derived cells naturally underwent an EMT response when aggregating into spheroids, and this was reversed upon spheroid re-attachment to a substratum. CDH1/E-cadherin expression was markedly reduced in spheroids compared with adherent cells, in concert with an up-regulation of several transcriptional repressors, i.e., SNAI1/Snail, TWIST1/2, and ZEB2. Treatment of EOC spheroids with the TGFβ type I receptor inhibitor, SB-431542, potently blocked the endogenous activation of EMT in spheroids. Furthermore, treatment of spheroids with SB-431542 upon re-attachment enhanced the epithelial phenotype of dispersing cells and significantly decreased cell motility and Transwell migration. Spheroid formation was significantly compromised by exposure to SB-431542 that correlated with a reduction in cell viability particularly in combination with carboplatin treatment. Thus, our findings are the first to demonstrate that intact TGFβ signaling is required to control EMT in EOC ascites-derived cell spheroids, and it promotes the malignant characteristics of these structures. As such, we show the therapeutic potential for targeted inhibition of this pathway in ovarian cancer patients with late-stage disease.

KEYWORDS:

EMT; TGFβ; metastasis; ovarian cancer; spheroid

PMID:
26647384
DOI:
10.1530/ERC-15-0383
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center